<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02999373</url>
  </required_header>
  <id_info>
    <org_study_id>Guangdong M And C</org_study_id>
    <nct_id>NCT02999373</nct_id>
  </id_info>
  <brief_title>Prevention of Preterm Infection by Autologous Umbilical Cord Blood Mononuclear Cells Therapy</brief_title>
  <official_title>Prevention of Preterm Infection by Autologous Umbilical Cord Blood Mononuclear Cells(CBMNC) Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong Women and Children Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangdong Women and Children Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      About 37% of neonatal mortality are caused by infection worldwidely . Excessive application
      of broad-spectrum antibiotics increased drug-resistance, however does not decrease morbility
      and mortality of neonates. Based on the investigator' early in vitro experiments which found
      cord blood mononuclear cells can inhibit bacterial growth and reduce of drug-resistance,
      along with other studies conducted recently from other groups who have reported the
      successful use of umbilical cord blood mononuclear cells in animal sepsis.The investigator
      would like to investigate the effects of umbilical cord blood mononuclear cells on prevention
      effect of preterm infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1 clinical trial that constitutes two time points cohorts with 80
      participants per cohort who will receive intravenous doses of Autologous Umbilical Cord Blood
      Mononuclear Cells --25 million cells/kg,6 hours or 48 hours after birth. And the placebo will
      be 0.9% sodium chloride.The investigator will proceed the groups during the same period.

        1. Eligibility Criteria:Preterm (gestational age more than 28weeks and less than 37weeks )

        2. Exclusion criteria:Preterm infants with major congenital malformations, chromosomal
           anomalies, inborn errors of metabolism and clinical or laboratory evidence of a
           congenital infection

        3. Demographic Data and Baseline Characteristics of the Studied Groups were collected :

           Gestational age (weeks) Birth weight (g) gender Cesarean section delivery Antenatal
           steroids Prolonged rupture of membrane Multiple pregnancies APGAR score at 5 minutes
           Thrombocytopenia before intervention CRP before intervention (mg/L) TNF-α(tumor necrosis
           factor α ) before intervention (pg/mL)

        4. Assessment of clinical condition in the course by measurement of arterial blood
           pressure, heart and respiratory rates and skin temperature was recorded continuously

        5. Autologous cord blood mononuclear cells doses is 25 million cells/kg ，the infusion speed
           is 4ml/kg/h， 8-12h，and with same volume of 0.9% sodium chloride as placebo.

           When the clinical symptoms suggests infection, blood cultures were performed before
           administration of antibiotics, and antibiotics were adjusted according to the
           susceptibility of the isolated bacteria.

        6. The following are monitored at 3、7、14、21days after birth :

           panels of cytokine and biomarkers(CRP、TNF-α、IL-6、IL-10、MCP-1) are examined by Elisa,
           circulating stem cell levels, immune cells subgroup ,platelet activation related markers
           CD62P、CD63 , number of megakaryocyte are evaluated by flow cytometry, infectious rate,
           mortality, incidence of multiple drug-resistant bacteria ,clinical complications:
           sepsis, bronchopulmonary dysplasia(BPD), retinopathy of prematurity (ROP), necrotising
           enterocolitis (NEC), intraventricular haemorrhage (IVH), anaemia before hospital
           discharge

        7. Long-term follow up: in 1m, 3m, 6m,1y: neurodevelopment [Bayley Scales of Infant],
           asthma, anemia and physique growth .
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 7, 2017</start_date>
  <completion_date type="Anticipated">July 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of patients infected of bacteria measured by blood culture</measure>
    <time_frame>up tp 21dyas after birth</time_frame>
    <description>infectious rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of patients with neurodevelopmental disorder assessed by Bayley Score</measure>
    <time_frame>up to 1 month, 3 months ,6 months and 1 year</time_frame>
    <description>Long term follow up: in 1month, 3months, 6months,and 1y: neurodevelopment assessed by Bayley Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients died before discharge from hospital</measure>
    <time_frame>up to 28days after birth</time_frame>
    <description>mortality before discharge from hospital</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Infection, Bacteroides</condition>
  <condition>Neonates Premature</condition>
  <condition>Neonatal Death</condition>
  <arm_group>
    <arm_group_label>CBMNC1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous Umbilical Cord Blood Mononuclear Cells Therapy 6 hours after birth ,dose is 25 million cells/kg ，the infusion speed is 4ml/kg/h， 8-12h，</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CBMNC2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous Umbilical Cord Blood Mononuclear Cells Therapy 48 hours after birth ,dose is 25 million cells/kg ，the infusion speed is 4ml/kg/h， 8-12h，</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% sodium chloride infusion 6 hours after birth ,the infusion speed is 4ml/kg/h， 8-12h，</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% sodium chloride infusion 48 hours after birth ,the infusion speed is 4ml/kg/h， 8-12h，</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Autologous Umbilical Cord Blood Mononuclear Cells Therapy</intervention_name>
    <description>Autologous Umbilical Cord Blood Mononuclear Cells Therapy in preterm for prevention of infection</description>
    <arm_group_label>CBMNC1</arm_group_label>
    <arm_group_label>CBMNC2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% Sodium Chloride</intervention_name>
    <description>0.9% Sodium Chloride in control group</description>
    <arm_group_label>Placebo1</arm_group_label>
    <arm_group_label>Placebo2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  twenty-eight weeks to thirty-seven weeks

        Exclusion Criteria:

          -  Preterm infants with major congenital malformations, chromosomal anomalies, inborn
             errors of metabolism and clinical or laboratory evidence of a congenital infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>28 Weeks</minimum_age>
    <maximum_age>36 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jie Yang, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangdong Women and Children Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhuxiao Ren, MD</last_name>
    <phone>+8613538984634</phone>
    <email>renzhx1990@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jie Yang</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>511442</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Yang, PHD</last_name>
      <phone>39151777</phone>
      <phone_ext>020</phone_ext>
      <email>jasjie_yang@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Ballen KK, Gluckman E, Broxmeyer HE. Umbilical cord blood transplantation: the first 25 years and beyond. Blood. 2013 Jul 25;122(4):491-8. doi: 10.1182/blood-2013-02-453175. Epub 2013 May 14. Review.</citation>
    <PMID>23673863</PMID>
  </reference>
  <reference>
    <citation>Mezey É, Nemeth K. Mesenchymal stem cells and infectious diseases: Smarter than drugs. Immunol Lett. 2015 Dec;168(2):208-14. doi: 10.1016/j.imlet.2015.05.020. Epub 2015 Jun 4. Review.</citation>
    <PMID>26051681</PMID>
  </reference>
  <reference>
    <citation>Wannemuehler TJ, Manukyan MC, Brewster BD, Rouch J, Poynter JA, Wang Y, Meldrum DR. Advances in mesenchymal stem cell research in sepsis. J Surg Res. 2012 Mar;173(1):113-26. doi: 10.1016/j.jss.2011.09.053. Epub 2011 Oct 24. Review.</citation>
    <PMID>22225756</PMID>
  </reference>
  <reference>
    <citation>Leung, Kam Tong; Lam, Hugh Simon; Chan, Kathy Yuen Yee, Decreased Frequency of Circulating CD34+Hematopoietic Stem/Progenitor Cells in Preterm Infants with Late-Onset Systemic Bacterial Infection,Blood,2014.124.21</citation>
  </reference>
  <reference>
    <citation>Lam HS, Cheung HM, Poon TC, Wong RP, Leung KT, Li K, Ng PC. Neutrophil CD64 for daily surveillance of systemic infection and necrotizing enterocolitis in preterm infants. Clin Chem. 2013 Dec;59(12):1753-60. doi: 10.1373/clinchem.2013.209536. Epub 2013 Sep 17.</citation>
    <PMID>24046202</PMID>
  </reference>
  <reference>
    <citation>Ho MS, Mei SH, Stewart DJ. The Immunomodulatory and Therapeutic Effects of Mesenchymal Stromal Cells for Acute Lung Injury and Sepsis. J Cell Physiol. 2015 Nov;230(11):2606-17. doi: 10.1002/jcp.25028. Review.</citation>
    <PMID>25913273</PMID>
  </reference>
  <reference>
    <citation>van den Berg JP, van Zwieteren N, Westerbeek EA, Garssen J, van Elburg RM. Neonatal modulation of serum cytokine profiles by a specific mixture of anti-inflammatory neutral and acidic oligosaccharides in preterm infants. Cytokine. 2013 Oct;64(1):188-95. doi: 10.1016/j.cyto.2013.07.002. Epub 2013 Aug 2.</citation>
    <PMID>23911205</PMID>
  </reference>
  <reference>
    <citation>Lam HS, Wong SP, Liu FY, Wong HL, Fok TF, Ng PC. Attitudes toward neonatal intensive care treatment of preterm infants with a high risk of developing long-term disabilities. Pediatrics. 2009 Jun;123(6):1501-8. doi: 10.1542/peds.2008-2061.</citation>
    <PMID>19482760</PMID>
  </reference>
  <reference>
    <citation>Strunk T, Inder T, Wang X, Burgner D, Mallard C, Levy O. Infection-induced inflammation and cerebral injury in preterm infants. Lancet Infect Dis. 2014 Aug;14(8):751-762. doi: 10.1016/S1473-3099(14)70710-8. Epub 2014 May 28. Review.</citation>
    <PMID>24877996</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2016</study_first_submitted>
  <study_first_submitted_qc>December 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2016</study_first_posted>
  <last_update_submitted>April 7, 2017</last_update_submitted>
  <last_update_submitted_qc>April 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangdong Women and Children Hospital</investigator_affiliation>
    <investigator_full_name>yangjie</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>prevention, infection, preterm, cord blood mononuclear cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Perinatal Death</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Bacteroides Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

